In RCC, DR-18 has been shown to enhance the activity of anti-CTLA-4 treatment, suggesting that AIM2’s modulation of immune pathways could be leveraged to improve immunotherapy outcomes (69). This evidence concerns the gene AIM2 and renal cell carcinoma.